Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ia bukan cadangan pelaburan.
Lysogene S.A. engages in the research and clinical development of gene therapy for neurodegenerative disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was founded in 2009 and is based in Neuilly-sur-Seine, France.
Soalan Lazim
Apakah simbol saham Lysogene?▼
Bergantung pada bursa, simbol saham mungkin berbeza. Sebagai contoh, di bursa Boerse Muenchen, saham Lysogene didagangkan di bawah simbol 4W4.MU.
Berapa ramai pekerja yang dimiliki oleh Lysogene?▼
Sehingga 2 November 2026, syarikat mempunyai 22 pekerja.
Lysogene terletak dalam sektor apa?▼
Lysogene beroperasi dalam sektor Lain-lain.
Bilakah Lysogene menyiapkan split saham?▼
Lysogene tidak mempunyai sebarang split baru-baru ini.
Di manakah ibu pejabat Lysogene?▼
Ibu pejabat Lysogene terletak di Neuilly-sur-Seine, Perancis.